朱华医生个人简介
博士、副研究员。主要从事新型放射性药物研制及临床转化，推动10余种核素探针用于临床。中国核学会放射性药物分会(首届)秘书长 (常务理事、联合创始人)、核化学与放射化学分会第九届理事，中华医学会核医学分会第十届青委。近5年，发表通讯/第一作者SCI论文21篇，申请国家发明专利十余项(4项授权)。获2项国家自然科学基金(1项在研)，2项国家重点研发计划(项目骨干)，北京市自然科学基金(优秀成果)，北京市“科技新星”、优秀人才培养“青年拔尖”，等多个项目支持，在研经费300 余万。
发表论文情况
近3年代表性论文(10 篇)：( †代表共同第一作者，*代表通讯作者)
1. Hua Zhu, Liu Fei, Yan Zhang, Jianhua Yang, Xiaoxia Xu, Xiaoyi Guo, Teli Liu, Nan Li, Lin Zhu, Hank F. Kung*, Zhi Yang*. [18F](2S,4R)-4-Fluoroglutamine as a PET indicator for bone marrow metabolism dysfunctional: From animal experiments to clinical application. Molecular Imaging and Biology. 2019. DOI: 10.1007/s11307-019-01319-4. (Q1, SCI 3.626)
2. Teli Liu†, Chen Liu†, Xiaoxia Xu, Fei Liu, Xiaoyi Guo, Nan Li, Xuejuan Wang, Jianhua Yang, Xing Yang, Hua Zhu*, Zhi Yang*. Preclinical evaluation and primary clinical study of Al18F-PSMA-BCH in PET imaging of prostate cancer. Journal of Nuclear Medicine, 2019, doi:10.2967/jnumed.118.221671. (Q1, SCI 7.439)
3. Fei Liu†, Xiaoxia Xu†, Hua Zhu†, Yan Zhang, Jianhua Yang, Lifang Zhang, Nan Li, Lin Zhu, Hank F. Kung*, Zhi Yang*. PET Imaging of 18F-(2S,4R)4-fluoroglutamine Accumulation in Breast Cancer: from Xenografts to Patients. Molecular Pharmaceutics. 2018, 15 (8), pp 3448-3455. (SCI IF 4.556 Q1 )
4. Feng Wang, Teli Liu, Liqiang Li, Xiaoyi Guo, Dongban Duan, Zhibo Liu, Hua Zhu*, Zhi Yang. Production, Quality Control of next-generation PET radioisotope Iodine-124 and its Thyroid Imaging. J Radio. Nucl. Chem. 2018, 318: 1999-2006. (SCI IF 1.2, Q2)
5. Xiaoyi Guo†, Hua Zhu†, Nina Zhou, Zuhua Chen, Teli Liu, Fei Liu, Xiaoxia Xu, Hongjun Jin, Lin Shen, Jing Gao*, and Zhi Yang*.Non-invasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients. Molecular Pharmaceutics. 2018, 15 (11), 5174–5182 (SCI IF 4.556 Q1 )
6. C Liu, TL Liu, N Zhang, YQ Liu, N Li, P Du, Y Yang, M Liu, K Gong, X Yang, H Zhu*, K Yan, Z Yang*. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45(11): 1852–1861. (SCI IF 7.7, Q1)
7. F Liu, TL Liu; XX Xu, XY Guo, N Li, CY Xiong, C Li, H Zhu*, Z Yang*. Design, Synthesis and Biological Evaluation of 68Ga-DOTA-PA1 for Lung Cancer: A Novel PET Tracer for Multiple Somatostatin Receptors Imaging. Molecular Pharmaceutics. 2018. 15, 619−628. (SCI IF 4.4).
8. Xie QH†, Zhu H†, Wang F, Meng XX, Ren QS, Xia CQ *, Yang Z*.Establishing Reliable 64Cu Production Process: From Target Plating to Molecular Specific Tumor Micro-PET Imaging. Molecules 2017, 22, 641. (SCI IF 2.86)
9. Hua Zhu†, Chuanke Zhao†, Fei Liu, Lixin Wang, Junnan Feng, Chengchao Shou*, Zhi Yang*. 125I-F56 peptide as radio-analysis agent targeting VEGFR1 in mice xenografted with human gastric tumor. ACS Med. Chem. Lett. 2017, 8, 266-269. (SCI IF 3.74) (20170120)
10. Wu Y†, Zhu H†, Zhang B, Liu F, Chen J, Wang Y, Wang Y, Zhang Z, Wu L, Si L, Xu H, Yao T, Xiao S, Xia Q, Zhang L, Yang Z*, Zhou D*. Synthesis of Site-Specific Radiolabeled Antibodies for Radioimmunotherapy via Genetic Code Expansion. Bioconjug Chem. 2016, 27(10), 2460–2468. († Equal Contribution) (IF 4.5, 20160912)
